SI2263691T1 - Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) - Google Patents

Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)

Info

Publication number
SI2263691T1
SI2263691T1 SI200332202T SI200332202T SI2263691T1 SI 2263691 T1 SI2263691 T1 SI 2263691T1 SI 200332202 T SI200332202 T SI 200332202T SI 200332202 T SI200332202 T SI 200332202T SI 2263691 T1 SI2263691 T1 SI 2263691T1
Authority
SI
Slovenia
Prior art keywords
rhumab
cancer
treatment
monoclonal anti
humanized monoclonal
Prior art date
Application number
SI200332202T
Other languages
Slovenian (sl)
Inventor
Hans Koll
Birgit Bossenmaier
Hans-Joachim Muller
Mark X. Sliwkowski
Stephen Michael Kelsey
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority claimed from EP10176072A external-priority patent/EP2263691B1/en
Publication of SI2263691T1 publication Critical patent/SI2263691T1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SI200332202T 2002-07-15 2003-07-11 Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) SI2263691T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39629002P 2002-07-15 2002-07-15
US48004303P 2003-06-20 2003-06-20
EP10176072A EP2263691B1 (en) 2002-07-15 2003-07-11 Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)

Publications (1)

Publication Number Publication Date
SI2263691T1 true SI2263691T1 (en) 2012-12-31

Family

ID=37003252

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200332099T SI1585966T1 (en) 2002-07-15 2003-07-11 Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
SI200332202T SI2263691T1 (en) 2002-07-15 2003-07-11 Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200332099T SI1585966T1 (en) 2002-07-15 2003-07-11 Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4

Country Status (3)

Country Link
CN (1) CN1835768A (en)
SI (2) SI1585966T1 (en)
ZA (1) ZA200500126B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157490A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
US9828635B2 (en) * 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
CN112703000B (en) 2018-07-23 2024-05-31 特雷维治疗股份有限公司 Treatment of chronic cough, shortness of breath and dyspnea

Also Published As

Publication number Publication date
CN1835768A (en) 2006-09-20
SI1585966T1 (en) 2012-02-29
ZA200500126B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
IL149820A0 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
GB2368796B (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
EP1607404A4 (en) Monoclonal antibody and hybridoma producing the same
IL166244A0 (en) Super humanized antibodies
TR200200472T2 (en) Dosages for treatment with anti-Erb B2 antibodies
DK2263691T3 (en) Treatment of cancer with the recombinant humanized monoclonal anti-ErbB2 antibody 2C4 (rhuMAb-2C4)
WO2004056312A3 (en) Immunoglobulin variants and uses thereof
EP1174148A4 (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
DK1187632T3 (en) Treatment with anti-ErbB2 antibodies
IL185754A0 (en) Novel anti-plgf antibody
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
EP1434799A4 (en) Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
SI2263691T1 (en) Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
AU2002346127A1 (en) Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
AU2003229799A1 (en) Novel humanized anti-vap-1 monoclonal antibody
EP1446416A4 (en) Tumor specific monoclonal antibodies
WO2004083387A3 (en) Anti-ganglioside antibodies and methods of use
IL165753A0 (en) Humanized monoclonal antibody nPAM4
GB0121727D0 (en) Monoclonal antibodies